Novelos Therapeutics and Lee's Pharmaceutical Sign Exclusive Collaboration Agreement in China for Cancer and Hepatitis Compounds

20-Dec-2007

Maximum binding capacity in ion exchange chromatography

High-throughput screening of 1536 samples in just 27 seconds: The fastest microplate reader on the market

Unique Automated Pathogen DNA Extraction and Broad-Range Molecular Diagnosis of Bacteria and Fungi

Novelos Therapeutics, Inc. announced that Novelos signed an exclusive license agreement with Lee's Pharmaceutical (HK) Ltd (which is 30% owned by Sigma-Tau Group through Defiante Farmaceutica Lda) to develop and commercialize in China, including Hong Kong and Macau, as well as in Taiwan, two of Novelos' compounds: NOV-002 for cancer and NOV-205 for hepatitis. NOV-002 is Novelos' lead compound in pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track.

Lee's Pharmaceutical will be responsible for the cost of all clinical development, regulatory submissions and commercialization of NOV-002 and NOV-205 in China. In addition to upfront and milestone payments, Novelos will receive 20-25% royalties from Lee's Pharm on net sales of NOV-002 and 12-15% royalties on net sales of NOV-205.

https://www.bionity.com/en/news/75967/novelos-therapeutics-and-lee-s-pharmaceutical-sign-exclusive-collaboration-agreement-in-china-for-cancer-and-hepatitis-compounds.html